U.S. FDA approved Merck’s ERVEBO (Ebola Zaire Vaccine, Live) for use in children 12 months of age and older
On Aug. 3, 2023, Merck announced that the U.S. Food and Drug Administration (FDA) had approved an expanded…
Emergent BioSolutions awarded 10-Year BARDA contract valued at $704 million for Ebanga treatment for Ebola
On Jul. 31, 2023, Emergent BioSolutions announced that it was awarded a 10-year contract by the Biomedical Advanced…
Circulating vaccine-derived poliovirus type 2 reported in United Republic of Tanzania and Kenya
On Jul. 28, 2023, the World Health Organization (WHO) reported circulating vaccine-derived poliovirus type 2 (cVDPV2) in the…
COVID vaccine uptake among hospital workers rose from 86% to 99% after implementation of mandate
On Jul. 28, 2023, COVID vaccine uptake among hospital workers at a Philadelphia teaching hospital rose from 86%…
U.S. FDA approved Ervebo first U.S.-licensed vaccine for prevention of Ebola virus disease
On Jul. 28, 2023, the U.S. Food and Drug Administration (FDA) approved Merck’s Ervebo, a vaccine for the…
Disease | FDA | Pharmaceutical | Therapeutics | Vaccine
U.S. FDA approved ABRYSVO, Pfizer’s vaccine for prevention of RSV in older adults
On May 31, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
Novavax’s Nuvaxovid received positive CHMP opinion for full marketing authorization for prevention of COVID in the EU
On May 26, 2023, Novavax announced that Nuvaxovid (NVX-CoV2373) had been recommended for full Marketing Authorization (MA) for…
U.S. FDA approved first Respiratory Syncytial Virus (RSV) vaccine
On May 3, 2023, the U.S. FDA approved GlaxoSmithKline’s Arexvy as the first respiratory syncytial virus (RSV) vaccine…
Study raised concerns SARS-CoV-2 evolution outpaces vaccine-generated antibodies
On Apr. 27, 2023, a NIAID-led Phase 2 trial compared two Pfizer bivalent mRNA COVID-19 boosters found that…
U.S. FDA approved PREVNAR 20, Pfizer’s 20-valent pneumococcal conjugate vaccine for infants and children
On Apr. 27, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
U.S. state-by-state analysis of COVID-19 impact revealed driving forces behind variations in health published in The Lancet
On Apr. 23, 2023, the most comprehensive state-by-state analysis of the impacts of COVID-19 across the USA, published…
U.S. spending $5 billion to speed up development of new COVID vaccines
On Apr. 10, 2023, the U.S. Department of Health and Human Services (HHS) announced it was spending over…
Pfizer RSV vaccine 82% effective vs severe infection in infants, final data showed
On Apr. 5, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | NIH | Therapeutics | Vaccine
Frequent testing reduced COVID-19 deaths in nursing facilities
On Apr. 4, 2023, National Institutes of Health (NIH) funded research was announced from the University of Rochester…
Moderna finalized agreement with Government of the Republic of Kenya to establish an mRNA manufacturing facility
On Mar. 30, 2023, Moderna and the Government of the Republic of Kenya announced they had finalized an…
Biotechnology | CDC | COVID-19 | Diagnostics | Life Science News | Vaccine
Tuberculosis in the U.S. increased slightly during 2022 although it remained lower than prepandemic years
On Mar. 24, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced that Tuberculosis (TB) in…
Biotechnology | COVID-19 | NIH | Pharmaceutical | Vaccine
SARS-CoV-2 infection weakens immune-cell response to vaccination
On Mar. 20, 2023, NIH scientists announced that the magnitude and quality of a key immune cellï¾’s response…
Agriculture | Biotechnology | Infectious Disease | Influenza | Life Science News | Therapeutics | Vaccine
Vaccine makers prep bird flu shot for humans ‘just in case’; rich nations lock in supplies
On Mar. 20, 2023, some of the world’s leading makers of flu vaccines said they could make hundreds…
Circulating vaccine-derived poliovirus type 2 (cVDPV2) reported in Indonesia
On Mar. 17, 2023, the Indonesia Ministry of Health notified the World Health Organization (WHO) of the detection…
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the…
Advisory Committee on Immunization Practices recommended universal Hepatitis B vaccination in adults aged 19-59 years
On Mar. 10, 2023, the U.S. Centers for Disease Control and Prevention (CDC) in a significant step toward…
Biotechnology | FDA | Life Science News | Measles | Vaccine
U.S. FDA approved intramuscular administration for Merck’s MMRV Vaccines: M-M-RII, VARIVAX, and ProQuad
On Mar. 6, 2023, Merck announced that the U.S. Food and Drug Administration had approved the addition of…
Moderna to make milestone payments to NIH for COVID vaccine
On Feb. 24, 2023, Moderna announced will make certain contingent development, commercial and regulatory milestone payments to the…
Health Canada authorized Moderna’s Omicron-targeting bivalent COVID-19 vaccine in children & cdolescents
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
Lancet study published on natural immunity protection by COVID variant
On Feb. 16, 2023, it was reported in the Lancet that protection from past infection against re-infection from…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Oncology | Therapeutics | Vaccine
CPRIT approved $12 million to bring top-flight cancer researchers to Lone Star State
On Feb. 15, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced a major step forward…
Moderna to provide free COVID-19 vaccines after U.S. public health emergency ends
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
NIH scientists develop mouse model to study Mpox virulence
On Feb. 14, 2023, scientists from the National Institute of Allergy and Infectious Diseases announced they had developed…
U.S. Government and Novavax extend partnership for 1.5 million additional doses of Novavax’ COVID-19 vaccine
On Feb. 13, 2023, Novavax announced a modification to its existing agreement with the U.S. Department of Health…
Bivalent boosters provided better protection against severe COVID-19
On Feb. 7, 2023, an NIH funded study by University of North Carolina reported that Bivalent booster vaccines…